The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Support side: New 13D filer — insiders or holders bought while this setup is live; see the timeline.
Radar 90 (high attention) · dilution pressure high · listing risk low · governance risk low · runway 0.8 mo · strongest signal: Equity line (Aug 4, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (convertible note, equity line). Base case is a discounted raise; the question is when, not if.
An activist has arrived at a company that needs cash — a potential catalyst, but any financing terms may favour the newcomer. A new active >5% holder appeared while the company is under cash or listing pressure - the classic precursor to a recapitalization, board change, or takeover at a discount.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing | 18 |
| Aug 13, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-13 (accepted 16:30 ET) filing | 34 |
| Aug 4, 2026 | ▼ Equity line | “equity line” language in 8-K (EX-10.4) filed 2026-08-04 filing | 51 |
| Aug 4, 2026 | ▼ Convertible note | “convertible note” language in 8-K (EX-99.1) filed 2026-08-04 filing | 42 |
| Aug 3, 2026 | · 13D amendment | Schedule 13D/A filed 2026-08-03 filing | 24 |
| Aug 3, 2026 | · 13D amendment | Schedule 13D/A filed 2026-08-03 filing | 24 |
| Jul 30, 2026 | ▲ New 13D filer | Schedule 13D filed 2026-07-30 filing | 45 |
| Jul 30, 2026 | · 13D amendment | Schedule 13D/A filed 2026-07-30 filing | 24 |
| Jul 27, 2026 | ▼ Convertible note | “convertible note” language in 8-K (EX-99.1) filed 2026-07-27 filing | 42 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~0.8 months runway: liquidity $830,193 as of 2026-06-30, burn $12,072,417/yr (annualized 272-day YTD operating cash flow [companyfacts]) filing | 49 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 626,860 (2026-05-14) -> 6,506,860 (2026-08-14), +938% filing | 45 |
| Jun 30, 2026 | ▼ Near $5M MVLS floor | Public float $4,111,262 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 27 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $830,193 vs current liabilities $10,399,528 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →